Market Closed -
Toronto S.E.
14:52:16 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
1.11
CAD
|
-5.13%
|
|
+11.00%
|
+23.33%
|
Fiscal Period: December |
2023
|
2024
|
---|
Capitalization
1 |
62.86
|
78.64
|
Enterprise Value (EV)
1 |
62.86
|
78.64
|
P/E ratio
|
-
|
-
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
179
x
|
184
x
|
EV / Revenue
|
179
x
|
184
x
|
EV / EBITDA
|
-
|
-3.97
x
|
EV / FCF
|
-
|
-13.8
x
|
FCF Yield
|
-
|
-7.25%
|
Price to Book
|
-
|
-
|
Nbr of stocks (in thousands)
|
69,847
|
70,847
|
Reference price
2 |
0.9000
|
1.110
|
Announcement Date
|
24-05-07
|
-
|
Fiscal Period: December |
2023
|
2024
|
---|
Net sales
1 |
0.351
|
0.428
|
EBITDA
1 |
-
|
-19.8
|
EBIT
1 |
-19.37
|
-17.2
|
Operating Margin
|
-5,519.37%
|
-4,018.69%
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
|
-
|
-
|
Net margin
|
-
|
-
|
EPS
|
-
|
-
|
Free Cash Flow
1 |
-
|
-5.7
|
FCF margin
|
-
|
-1,331.78%
|
FCF Conversion (EBITDA)
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
24-05-07
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
0.077
|
0.099
|
0.097
|
0.101
|
0.105
|
0.109
|
0.113
|
EBITDA
1 |
-
|
-2.38
|
-3.173
|
-
|
-4.8
|
-4.9
|
-5
|
-5.1
|
EBIT
1 |
-
|
-2.982
|
-3.934
|
-7.408
|
-4.3
|
-4.3
|
-4.2
|
-4.3
|
Operating Margin
|
-
|
-3,872.73%
|
-3,973.74%
|
-7,637.11%
|
-4,257.43%
|
-4,095.24%
|
-3,853.21%
|
-3,805.31%
|
Earnings before Tax (EBT)
|
-
|
-12
|
-4.214
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-4.681
|
-11.97
|
-4.193
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-15,550.65%
|
-4,235.35%
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-0.0900
|
-0.2800
|
-0.0600
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23-06-29
|
23-08-29
|
23-11-29
|
24-05-07
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
Net Cash position
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
Free Cash Flow
1 |
-
|
-5.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
Assets
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
Capex
1 |
-
|
0.05
|
Capex / Sales
|
-
|
11.68%
|
Announcement Date
|
24-05-07
|
-
|
Last Close Price
1.11
CAD Average target price
2.75
CAD Spread / Average Target +147.75% Consensus |
1st Jan change
|
Capi.
|
---|
| +23.33% | 57.56M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|